• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RIMONABANT Drug Record

  • Summary
  • Interactions
  • Claims
  • RIMONABANT chembl:CHEMBL111

    Alternate Names:

    SR-141716
    SR-141716A
    ACOMPLIA
    SR-14171
    RIMONABANT
    SR 141716
    A 281
    chemidplus:168273-06-1
    pubchem.compound:104850
    chembl:CHEMBL111
    drugbank:06155

    Drug Info:

    FDA Approval not approved
    Drug Class Small Molecule
    Drug Indications antiobesity agent
    Drug Class appetite-depressants
    Year of Approval not approved by the fda
    (0 More Sources)

    Publications:

    Wu CH et al., 2009, Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice., J Med Chem
    Manca I et al., 2013, Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake., Eur J Med Chem
    Cawston EE et al., 2015, Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors., J Med Chem
    Tseng SL et al., 2008, Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists., J Med Chem
    Kumar Srivastava B et al., 2008, Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist., Bioorg Med Chem Lett
    Shire et al., 1996, Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A., J. Biol. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Wittgen HG et al., 2011, Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4., Drug Metab Dispos
  • RIMONABANT   CNR1

    Interaction Score: 2.76

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Rimonabant
    Novel drug target Established target

    PMIDs:
    19530697 23357307 26203658 18712856 18585913 8636122 11752352


    Sources:
    DTC TdgClinicalTrial TEND

  • RIMONABANT   ABCC3

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21511945


    Sources:
    DTC

  • RIMONABANT   ABCC4

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21511945


    Sources:
    DTC

  • RIMONABANT   ABCC1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21511945


    Sources:
    DTC

  • RIMONABANT   ABCC2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21511945


    Sources:
    DTC

  • RIMONABANT   GMNN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RIMONABANT   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: RIMONABANT

    • Version: 01-August-2011

    Alternate Names:
    RIMONABANT Primary Drug Name

    Drug Info:
    Year of Approval not approved by the fda
    Drug Class appetite-depressants

    Publications:

  • TdgClinicalTrial: RIMONABANT

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiobesity agent
    Drug Class Small Molecule
    FDA Approval not approved

    Publications:

  • DTC: RIMONABANT

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL111 ChEMBL Drug ID

    Drug Info:

    Publications:
    Manca I et al., 2013, Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake., Eur J Med Chem
    Tseng SL et al., 2008, Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists., J Med Chem
    Wu CH et al., 2009, Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice., J Med Chem

  • ChemblDrugs: chembl:CHEMBL111

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21